FAQs on Mifepristone Safety, Access, Current Legislation, and the Pharmacist’s Role

This FAQ was fact-checked by Sally Rafie, PharmD, APP, BCPS, FCCP, FCPhA.

As legal and political challenges surrounding reproductive health care continue to evolve in the US, pharmacists are increasingly navigating complex questions about the laws, regulations, and dispensing requirements of mifepristone (Mifeprex; Danco Laboratories). Although mifepristone has more than 25 years of clinical use and a substantial evidence base supporting its safety and efficacy, ongoing litigation, shifting federal policies, and a patchwork of state laws have created uncertainty for both patients and health care professionals.

Pharmacists now play a critical role not only in dispensing and ensuring compliance with the FDA’s Risk Evaluation and Mitigation Strategies (REMS) program, but also in counseling patients, protecting patient confidentiality, and staying informed about rapidly changing legal developments.

This FAQ reviews the clinical pharmacology of mifepristone, current dispensing regulations as of May 2026, and practical considerations for pharmacists when caring for patients seeking medication pregnancy termination or other evidence-based uses of mifepristone.

Q1: What is mifepristone and how does it work?

Mifepristone is a synthetic progesterone receptor antagonist (antiprogestin) approved by the FDA in 2000 under the brand name Mifeprex. Since 2019, it is also available in an FDA-approved generic formulation. Its primary approved indication is medical termination of intrauterine pregnancy through 70 days (10 weeks) gestation, used in a sequential regimen with misoprostol. It is used off-label for early pregnancy loss, also referred to as miscarriage management, and medical termination of intrauterine pregnancy through 77 days (11 weeks) gestation. Mifepristone is also approved under the brand name Korlym (Corcept Therapeutics) for controlling hyperglycemia in adults with Cushing syndrome, but that does not have a REMS program.

Mifepristone competitively blocks progesterone receptors in the uterine lining. Because progesterone is essential to maintaining a pregnancy, blocking these receptors causes thinning of the endometrial lining, detachment of the pregnancy, and sensitivity to prostaglandins. Mifepristone is followed 24 to 48 hours later by misoprostol, causing cervical softening and increased uterine contractility. This combination achieves complete pregnancy termination in approximately 95% to 98% of cases.

Q2: What are the main clinical indications and dosing?

For medication pregnancy termination, the FDA-approved regimen is 200 mg mifepristone orally followed 24 to 48 hours later by 800 mcg misoprostol buccally (or vaginally or sublingually, per clinical protocols).

Off-label uses include miscarriage management (incomplete or missed abortion), where it is used with misoprostol in a similar sequential regimen.

Q3: Is mifepristone safe? What does the evidence say?

Yes. Over 25 years of real-world use and extensive clinical research consistently support mifepristone's safety. A 2026 JAMA analysis reviewing thousands of pages of internal FDA documents from 2011 to 2023 confirmed that the agency's history of decisions on mifepristone has been based on science and safety data. Key data points include the following¹:

• serious complications requiring hospitalization occur in less than 1% of cases;
• the major complication rate cited in FDA surveillance data and independent studies is markedly lower than figures cited by critics;
• death is exceedingly rare, with the estimated mortality being lower than that associated with surgical abortion and many common medications;
• a 2024 JAMA Internal Medicine study² confirmed the safety of mail-order pharmacy dispensing following in-person screening;
• and Canada removed all dispensing restrictions on mifepristone without adverse safety signals.

The mainstream medical consensus—including from American College of Obstetricians and Gynecologists, Society of Family Planning, American College of Nurse-Midwives, and major pharmacy organizations—is that mifepristone is safe and effective, and that the existing REMS requirements are not supported by the evidence base applied to comparable drugs.

Q4: What is the Mifepristone REMS Program?

The Mifepristone REMS Program, which was established in 2011 and last substantially revised in January 2023, currently requires 3 main elements:

1. Prescriber certification. Prescribers must complete and submit a Prescriber Agreement Form to become certified before prescribing mifepristone 200 mg tablets for any indication.
2. Pharmacy certification. Pharmacies must complete a Pharmacy Agreement Form and comply with all REMS requirements to dispense mifepristone 200 mg tablets.
3. Patient agreement. Patients must review and sign an FDA Patient Agreement Form before receiving the prescription and/or medication from their prescriber, and a copy must be provided to the patient along with the FDA Medication Guide.

Q5: How does a pharmacy become certified to dispense mifepristone?

To become certified, a pharmacy—through an authorized representative, typically the pharmacist-in-charge or owner—must:

• Complete and submit the Pharmacy Agreement Form available through the mifepristone REMS Program (accessible via the manufacturer's REMS portal — Danco Laboratories for Mifeprex, and GenBioPro for the generic)
• Ensure the pharmacy can verify that each prescription for mifepristone is issued by a certified prescriber before dispensing
• Ensure that mifepristone is delivered or picked up within four calendar days of the pharmacy receiving the prescription — if this cannot be met, the certified prescriber must be contacted to determine whether dispensing is still appropriate
• Be able to receive Prescriber Agreement Forms by email and fax as needed for verification
• Protect patient confidentiality; the REMS includes explicit confidentiality provisions to protect patient and prescriber information.

Q6: What are the dispensing requirements my pharmacy staff must follow once certified?

Once certified, every dispensing of mifepristone must follow these steps:

• Verify the prescriber is certified under the REMS before dispensing — the prescription alone does not suffice if the prescriber is not certified
• Dispense mifepristone in its original packaging and record in the patient’s record the NDC and lot number from each package of mifepristone dispensed
• Confirm with the prescriber the appropriateness of dispensing mifepristone for patients who will receive the drug more than 4 calendar days after the date the pharmacy receives the prescription, and document the prescriber’s decision
• Maintain records as required by the REMS Program
• Full requirements are listed in the Pharmacy Agreement Form

Q7: What state laws affect pharmacy dispensing of mifepristone?

This is one of the most complex areas for pharmacists. The patchwork of state laws creates significant operational complexity:

• 13 states currently enforce total bans on abortion care, and in those states, dispensing mifepristone for pregnancy termination is generally prohibited regardless of federal REMS status.
• Additional states have gestational limits, prescriber restrictions, or other requirements that restrict when and how mifepristone can be legally dispensed
• Several states (eg, California, New York, Colorado) have “shield laws” designed to protect health care professionals who prescribe or dispense mifepristone to out-of-state patients, but these protections are being actively litigated.
• In states where abortion is legal, mifepristone dispensing is generally permitted under the federal REMS (subject to any current court orders).
• Telehealth prescribing of mifepristone from one state to a patient in another state is a growing area of legal conflict, including the first criminal indictment of a provider in Louisiana (January 2025) for prescribing via telehealth to a minor in Louisiana.

Because of a variety of state-specific legislation, pharmacists must know the law in their specific state and should consult legal counsel when in doubt.

Q8: What counseling should a pharmacist provide when dispensing mifepristone?

Effective counseling for mifepristone includes ensuring the patient understands what to expect and what to do if problems arise:

• Review the full 2-drug regimen. Mifepristone is taken first orally, followed by misoprostol buccally 24–48 hours later. Ask the patient to repeat back how they will take the medications.
• Cramping and bleeding typically begin within 1 to 4 hours of misoprostol. Heavier than normal period-like bleeding is expected and will diminish over days to weeks.
• Warn patients about symptoms requiring emergency care, including sustained fever of 100.4°F or higher, severe abdominal pain, soaking 2 or more pads per hour for 2+ hours, foul-smelling discharge, or feeling generally ill or weak for more than 24 hours after initiation of medication.
• Confirm patients know who to call and where to go for emergencies.
• Review the FDA Medication Guide with the patient and ensure they have a copy.
• Discuss follow-up. Patients typically need a follow-up appointment at 7 to 14 days to confirm complete termination. Some providers use a symptom-based check or at-home pregnancy test per current evidence-based protocols.

Q9: How can pharmacists support patients who cannot access mifepristone due to state laws or legal uncertainty?

Pharmacists occupy a unique and trusted position in health care. In states where mifepristone access is limited, there are several ways pharmacists can support patients within the law:

• Provide accurate, nonjudgmental information about what is legally available in the individual patient’s state.
• Know and share referral resources such as national organizations and Planned Parenthood, who can help connect patients with providers in accessible states.
• In states where misoprostol-only regimens are legal and prescribed, pharmacists can counsel patients that misoprostol alone (without mifepristone) has approximately 80% efficacy—significantly lower than the combination regimen—and review its specific regimen and possible adverse effects.
• If practicing in a state with shield law protections patients from restricted states are treated, pharmacists should consult legal counsel about what is legally protected under both federal and state.
• Maintain confidentiality rigorously. Reproductive health information should be handled with the highest level of privacy.
• Stay informed about Aid Access, Plan C, and similar organizations that help connect patients with resources, and provide factual information when needed.

More information and resources can be found at medicationabortionpharmacies.com.

REFERENCES

1. Dilek S, Rosen J, Levashkevich A, Sharfstein JM, Alexander GC. The US Food and Drug Administration’s Regulation of Mifepristone. JAMA. 2026;335(7):619–625. doi:10.1001/jama.2025.23091

2. Grossman D, Raifman S, Morris N, et al. Mail-Order Pharmacy Dispensing of Mifepristone for Medication Abortion After In-Person Screening. JAMA Intern Med. 2024;184(8):873–881. doi:10.1001/jamainternmed.2024.1476